The DREAMM-2 Trial in RRMM


Principal investigator Sagar Lonial, MD, FACP, discusses the DREAMM-2 trial and relapsed/refractory multiple myeloma.

Sagar Lonial, MD, FACP: Belantamab mafodotin [belamaf], was approved based on the DREAMM-2 study [NCT03525678]. DREAMM-2 was a randomized, phase 2 trial of belantamab mafodotin in patients with a median of 6 to 7 prior lines of therapy. In the context of this trial, patients were randomized to receive either 3.4 mg/kg of belamaf—which was the dose that was arrived at in the phase 1 study—or 2.5 mg/kg of belamaf, a dose that was suggested by the FDA as a way to try to reduce the incidence of keratopathy, the known and most common adverse event associated with the immunotoxin MMAF, which is what the BCMA [B-cell maturation antigen] antibody is linked with in belantamab mafodotin. We saw an overall response rate of [approximately] 30% in both arms, slightly higher with the higher dose. PFS [progression-free survival] was around 3 months for both arms… What was striking about this trial was that the duration of response [DOR] in the lower dose was 11 months [but it was] much shorter in the higher dose of belamaf. [Although] many may be perplexed by this, the reality is that the higher dose of belamaf was more difficult to give and was associated with more adverse events and higher-grade keratopathy. The reason the lower dose was chosen was that it appeared to be a safe, effective dose that did not [affect] how long responding patients could stay on therapy. It had a 30% response rate, median PFS of [approximately] 3 months, and a DOR of 11 months for the 2.5 mg/kg dose. When one looks at the FDA-approval trials for carfilzomib, daratumumab, and pomalidomide, they all look relatively similar. In fact, the 11 months with BCMA looks somewhat better, given that this was a median of 6 to 7 prior lines of therapy, and patients had all been exposed to carfilzomib, pomalidomide, and daratumumab prior to study entry. Overall, the safety and efficacy data from DREAMM-2 look favorable and led to the FDA approval of belamaf in the patient population. Additionally, what we did—and what was looked at ASH [Alliance for Shared Health] this year, as well as ASCO [American Society of Clinical Oncology Annual Meeting]—was look at responses based on prior therapy, and patients who had fewer than 6 lines of therapy were compared with patients who had more than 6 lines of prior therapy. We demonstrated that the response rate was similar between the 2, suggesting that because BCMA is a novel target, the efficacy of belamaf was not [affected] significantly by a lot of heavily pretreated patients vs less heavily pretreated patients across the board; remember, almost all the patients in this trial were triple-class refractory.

Transcript edited for clarity.

A 72-Year-Old Man with Heavily Pretreated, R/R Multiple Myeloma

Initial Presentation

  • A 72-year-old man diagnosed with multiple myeloma 4.5 years ago returns for routine follow up
  • Treatment history:
  • Initially treated with VRd for 12 months, followed by lenalidomide maintenance 15 mg daily; stable disease lasting 36 months
  • Rechallenged with VRd, stable disease lasting 20 months
  • Subsequently switched to KPd, achieved a partial response lasting 15 months
  • Started DVd; follow up at 12 months showed M protein increase by 0.5 g/dl; patient continues to feel well 
  • Currently, 3 months after his last visit, he returns to the clinic complaining of increased muscle weakness, fatigue and bone pain
  • PE: new bony tenderness appreciated on ribs, bruising, mild bleeding of the gums

Clinical Workup

  • Labs: Hb 8.8 g/dL, calcium 10.2 mg/dL, LDH 160 U/L, creatinine 2.1 mg/dL, albumin 3.0 g/dL, b2 microgloblulin 4.9 mcg/mL, serum M-protein 4.2 g/dL, lambda free light chains 4.1 mg/dL
  • HBV negative
  • Skeletal survey and MRI revealed stable lytic bone lesions in the left hip, pelvis and L2 vertebrae and new lytic lesions on the ribs 4 and 10 on the left side
  • Bone marrow shows 70% plasma cells IgG k
  • FISH: t(6;14) (p21;q32) at diagnosis; new del(17p)
  • Diagnosis: R-ISS stage II MM
  • ECOG 1


  • Initiated treatment with belantamab mafodotin
Related Videos
Expert on GVHD
Expert on GVHD
Experts on GVHD
Eytan M. Stein, MD, an expert on myelodysplastic syndrome
Experts on lymphoma
Experts on lymphoma
Related Content